Sutro Biopharma, Inc. (STRO)
| Market Cap | 211.24M |
| Revenue (ttm) | 53.12M |
| Net Income (ttm) | -114.29M |
| Shares Out | 47.58M |
| EPS (ttm) | -2.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 540,110 |
| Open | 4.41 |
| Previous Close | 4.38 |
| Day's Range | 4.17 - 4.52 |
| 52-Week Range | 4.17 - 23.70 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 29.84 (+572.1%) |
| Earnings Date | May 6, 2022 |
About STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate rec...
Financial Performance
In 2021, STRO's revenue was $61.88 million, an increase of 44.84% compared to the previous year's $42.72 million. Losses were -$105.54 million, 228.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for STRO stock is "Buy." The 12-month stock price forecast is 29.84, which is an increase of 572.07% from the latest price.
News
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
- Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 -
Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , April 29, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focus...
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif. , April 8, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focuse...
Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...
Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual ...
SOUTH SAN FRANCISCO, Calif. , March 30, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focus...
Sutro Biopharma, Inc. (STRO) Moves 6.4% Higher: Will This Strength Last?
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength ...
Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 3, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...
7 Triple-F-Rated Stocks That Have No Hope in Sight
The contrarian in a lot of people perks up during selloffs like the one we're in right now, but don't let these F-rated stocks tempt you. The post 7 Triple-F-Rated Stocks That Have No Hope in Sight appe...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO
New York, New York--(Newsfile Corp. - February 3, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO). Such investors ...
SHAREHOLDER ALERT: Investigation of Sutro Biopharma, Inc. Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 18, 2022) - Holzer & Holzer, LLC is investigating whether Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO) complied with federal securities law...
Why Sutro Biopharma Stock Is Losing Ground Today
Phase 1 data for its ovarian cancer candidate was a little disappointing.
Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused ...
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advance...
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused ...
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on ...
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugat...
SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro"), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicat...
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
Sutro Biopharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...
Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors
SOUTH SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise prot...
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 0.00% and -3.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...
Sutro Biopharma to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...